BioLargo (BLGO) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 13, 2022
Document Information [Line Items]
Entity Central Index Key	0000880242
Entity Registrant Name	BIOLARGO, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-19709
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	65-0159115
Entity Address, Address Line One	14921 Chestnut St.
Entity Address, City or Town	Westminster
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92683
City Area Code	888
Local Phone Number	400-2863
Title of 12(b) Security	Common stock
Trading Symbol	BLGO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		262,684,267

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 974,000	$ 962,000
Accounts receivable, net of allowance	690,000	513,000
Inventories, net of allowance	270,000	241,000
Prepaid expenses and other current assets	114,000	85,000
Total current assets	2,048,000	1,801,000
Equipment and leasehold improvements, net of depreciation	90,000	61,000
Other non-current assets	99,000	69,000
Investment in South Korean joint venture	40,000	48,000
Right of use operating lease, net of amortization	421,000	453,000
Clyra Medical prepaid marketing (Note 8)	591,000	591,000
Total assets	3,289,000	3,023,000
Current liabilities:
Debt obligations, net of discount and amortization (Note 4)	174,000	314,000
Deferred revenue	0	89,000
Customer deposits	91,000	79,000
Lease liability	103,000	103,000
Total current liabilities	1,244,000	1,374,000
Long-term liabilities:
Long-term debt, noncurrent	150,000	180,000
Lease liability	318,000	349,000
Total long-term liabilities	645,000	716,000
Total liabilities	1,889,000	2,090,000
COMMITMENTS AND CONTINGENCIES (Note 10)
STOCKHOLDERS’ EQUITY :
Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at March 31, 2022 and December 31, 2021	0	0
Common stock, $0.00067 Par Value, 400,000,000 Shares Authorized, 262,684,267 and 255,893,726 Shares Issued, at March 31, 2022 and December 31, 2021	176,000	171,000
Additional paid-in capital	145,205,000	143,718,000
Accumulated deficit	(140,773,000)	(139,121,000)
Accumulated other comprehensive loss	(123,000)	(115,000)
Total BioLargo Inc. and subsidiaries stockholders’ equity	4,485,000	4,653,000
Non-controlling interest (Notes 8)	(3,085,000)	(3,720,000)
Total stockholders’ equity	1,400,000	933,000
Total liabilities and stockholders’ equity	3,289,000	3,023,000
Entities, Excluding Partially Owned Subsidiary [Member]
Current liabilities:
Accounts payable and accrued expenses	672,000	559,000
Long-term liabilities:
Long-term debt, noncurrent	150,000	180,000
Partially Owned Subsidiary [Member]
Current liabilities:
Accounts payable and accrued expenses	204,000	230,000
Long-term liabilities:
Long-term debt, noncurrent	$ 177,000	$ 187,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00067	$ 0.00067
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	262,684,267	255,893,726

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 965,000	$ 571,000
Cost of revenue
Cost of Goods and Services Sold	(444,000)	(339,000)
Gross profit	521,000	232,000
Operating expenses:
Selling, general and administrative expenses	1,839,000	1,763,000
Research and development	392,000	327,000
Total operating expenses	2,231,000	2,090,000
Operating loss	(1,710,000)	(1,858,000)
Other income (expense):
Grant income	5,000	30,000
PPP loan forgiveness	174,000	43,000
Interest expense	(13,000)	(93,000)
Total other income (expense)	166,000	(20,000)
Net loss	(1,544,000)	(1,878,000)
Net income (loss) attributable to noncontrolling interest	108,000	(247,000)
Net loss attributable to common shareholders	$ (1,652,000)	$ (1,631,000)
Net loss per share attributable to common stockholders:
Loss per share attributable to shareholders – basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding: (in shares)	260,805,418	233,733,015
Comprehensive loss attributable to common shareholders
Net loss	$ (1,544,000)	$ (1,878,000)
Foreign translation adjustment	(8,000)	(2,000)
Comprehensive loss	(1,552,000)	(1,880,000)
Comprehensive income (loss) attributable to noncontrolling interest	108,000	(247,000)
Comprehensive loss attributable to shareholders	(1,660,000)	(1,633,000)
Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	610,000	444,000
Cost of revenue
Cost of Goods and Services Sold	(293,000)	(237,000)
Service [Member]
Revenue from Contract with Customer, Including Assessed Tax	355,000	127,000
Cost of revenue
Cost of Goods and Services Sold	$ (151,000)	$ (102,000)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Clyra Medical Technology Inc [Member]Common Stock [Member]	Clyra Medical Technology Inc [Member]Additional Paid-in Capital [Member]	Clyra Medical Technology Inc [Member]Retained Earnings [Member]	Clyra Medical Technology Inc [Member]AOCI Attributable to Parent [Member]	Clyra Medical Technology Inc [Member]Noncontrolling Interest [Member]	Clyra Medical Technology Inc [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance, December 31, 2021 (in shares) at Dec. 31, 2020							225,885,682
Balance, December 31, 2021 at Dec. 31, 2020							$ 151,000	$ 135,849,000	$ (132,041,000)	$ (101,000)	$ (4,093,000)	$ (235,000)
Sale of common stock for cash (in shares)							13,330,619
Sale of common stock for cash							$ 9,000	2,097,000	0	0	0	2,106,000
Issuance of common stock for service (in shares)							747,487
Issuance of common stock for service							$ 1,000	110,000	0	0	0	111,000
Stock option compensation expense	$ 0	$ 161,000	$ 0	$ 0	$ 0	$ 161,000		424,000				424,000
Net loss							0	0	(1,631,000)		(247,000)	(1,878,000)
Foreign currency translation							0	0	0	(2,000)		(2,000)
Warrant and conversion feature issued as discount on convertible note payable							0	35,000	0	0	0	35,000
Clyra Medical securities offering	0	0	0	0	50,000	50,000
Allocation of noncontrolling interest from Clyra Stock option issuance							$ 0	(313,000)	0	0	313,000	0
Balance (in shares) at Mar. 31, 2021							239,963,788
Balance at Mar. 31, 2021							$ 161,000	138,363,000	(133,672,000)	(103,000)	(3,977,000)	772,000
Balance, December 31, 2021 (in shares) at Dec. 31, 2020							225,885,682
Balance, December 31, 2021 at Dec. 31, 2020							$ 151,000	135,849,000	(132,041,000)	(101,000)	(4,093,000)	(235,000)
Balance (in shares) at Dec. 31, 2021							255,893,726
Balance at Dec. 31, 2021							$ 171,000	143,718,000	(139,121,000)	(115,000)	(3,720,000)	933,000
Sale of common stock for cash (in shares)							6,703,789
Sale of common stock for cash							$ 4,000	1,198,000	0	0	0	1,202,000
Issuance of common stock for service (in shares)							86,752
Issuance of common stock for service							$ 0	17,000	0	0	0	17,000
Stock option compensation expense	$ 0	$ 141,000	$ 0	$ 0	$ 0	$ 141,000	0	660,000	0	0	0	660,000
Noncontrolling interest allocation							0	(528,000)	0	0	528,000	0
Net loss							0	0	(1,652,000)	0	108,000	(1,544,000)
Foreign currency translation							$ 0	0	0	(8,000)	0	(8,000)
Balance (in shares) at Mar. 31, 2022							262,684,267
Balance at Mar. 31, 2022							$ 176,000	$ 145,205,000	$ (140,773,000)	$ (123,000)	$ (3,085,000)	$ 1,400,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (1,544,000)	$ (1,878,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	801,000	585,000
Common stock issued in lieu of salary to officers and fees for services from vendors	17,000	111,000
Interest expense related to amortization of the discount on convertible notes payable and line of credit	4,000	46,000
PPP loan forgiveness	(174,000)	(43,000)
Loss on investment in South Korean joint venture	8,000	10,000
Bad debt expense	0	1,000
Depreciation expense	2,000	7,000
Changes in assets and liabilities:
Accounts receivable	(178,000)	206,000
Inventories	(29,000)	36,000
Deferred revenue	(89,000)	(4,000)
Prepaid expenses and other current assets	(59,000)	(34,000)
Customer deposits	12,000	80,000
Net cash used in operating activities	(1,140,000)	(845,000)
Cash flows from investing activities
Purchase of equipment	(32,000)	(10,000)
Net cash used in investing activities	(32,000)	(10,000)
Cash flows from financing activities
Proceeds from sales of common stock	1,202,000	2,106,000
Payment of debt obligations	0	(650,000)
Payment of Clyra Medical debt obligations	(10,000)	(24,000)
Net cash provided by financing activities	1,192,000	1,482,000
Net effect of foreign currency translation	(8,000)	(2,000)
Net change in cash	12,000	625,000
Cash at beginning of year	962,000	716,000
Cash at end of period	974,000	1,341,000
Supplemental disclosures of cash flow information
Interest	7,000	26,000
Income taxes	0	0
Non-cash investing and financing activities
Fair value of warrants issued with convertible notes	0	35,000
Conversion of intercompany receivable to Clyra shares (Note 8)	633,000,000	0
Allocation of noncontrolling interest	528,000	313,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sales of common stock	0	50,000
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	114,000	(98,000)
Accounts payable and accrued expenses	114,000	(98,000)
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	(25,000)	130,000
Accounts payable and accrued expenses	$ (25,000)	$ 130,000

Note 1 - Business and Organizat

Note 1 - Business and Organization	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air and a cleaner earth. The company also owns a majority interest in a medical products subsidiary that has licensed BioLargo’s technologies. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Liquidity / Going concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. For the three March 31, 2022, March 31, 2022, three March 31, 2022, 9. one None We do not December 31, 2022, 3. If we are unable to rely on our current arrangement with Lincoln Park to continue to fund our working capital requirements, we will have to rely on other forms of financing, and there is no The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to continue to raise funds through stock sales to Lincoln Park or other private financings, and in the long term, our ability to attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technologies. The consolidated financial statements do not Organization We are a Delaware corporation formed in 1991. four 2006; 2009; 2019, 2014; 2016. 2017. 2012, 2, Principles of Consolidation 8 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, not three March 31, 2022, not may December 31, 2022, 10 December 31, 2021, March 31, 2022.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. In the opinion of management, the accompanying balance sheet and related statements of operations, cash flows, and stockholders’ deficit include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and partially-owned subsidiaries BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated. Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of March 31, 2022 December 31, 2021, March 31, 2022 December 31, 2021 BioLargo, Inc. and subsidiaries $ 951 $ 941 Clyra Medical Technologies, Inc. 23 21 Total $ 974 $ 962 Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of March 31, 2022 December 31, 2021, $ 13,000 Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three March 31, 2022 2020, 10% March 31, 2022 March 31, 2021 Customer A 29 % <10 % Customer B 14 % <10 % Customer C <10 % 39 % Customer D <10 % 16 % Customer E <10 % 13 % Customer F <10 % 12 % We had two customers that each accounted for more than 10% March 31, 2022, two December 31, 2021, March 31, 2022 December 31, 2021 Customer D 29 % <10 % Customer E 24 % <10 % Customer F <10 % 32 % Customer G <10 % 12 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of March 31, 2022, December 31, 2021, $3,000. March 31, 2022 December 31, 2021 Raw material $ 129 $ 108 Finished goods 141 133 Total $ 270 $ 241 Other Assets Other non-current assets consisted of (i) security deposits of $35,000 related to our business offices, and (ii) three $29,000. Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not three March 31, 2022 March 31, 2021 Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not three March 31, 2022 2021, Nevertheless, for the year ended December 31, 2021, 2021 $342,000. Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three March 31, 2022 2021, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three March 31, 2022 2021: 2022 2021 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.32 % 2.32 % 1.73 % 0.93 – 1.73% Expected volatility 117 % 117 % 124 % 124% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible debt instrument is examined for any intrinsic beneficial conversion feature (“BCF”) of which the conversion price is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible debt instrument and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. At present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered, or product is received. Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: We have revenue from four BLEST identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. BLEST’s contracts typically call for invoicing for time and materials incurred for that contract. A few contracts have called for milestone or fixed cost payments, where BLEST invoices an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. We recognized $118,000 in the three March 31, 2022, December 31, 2021. March 31, 2022, no In the event that we generate revenues from royalties or license fees from our intellectual property, we anticipate a licensee would pay a license fee in one Government Grants We have been awarded multiple research grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no March 31, 2022, December 31, 2021. The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not March 31, 2022. The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized. Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of March 31, 2022 December 31, 2021, Tax Credits Our research and development activities in Canada may not Leases We adopted ASU 2016 12 842, No March 31, 2022, $ 421,000 Recent Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 1 not not 2 December 15, 2021, December 15, 2023, not In January 2020, No 2020 01, 321 323 815 321, 323, 815”. 321 323 2016 01. 321 10 35 2, 321 not

Note 3 - Sale of Stock for Cash

Note 3 - Sale of Stock for Cash	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 3. Lincoln Park Financing During the three March 31, 2022 2021, 2020 During the three March 31, 2022, May 2020, eleven six five 6, 2020 During the three March 31, 2021, May 2020, three six five 6, 2020

Note 4 - Debt Obligations

Note 4 - Debt Obligations	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. The following table summarizes our debt obligations outstanding as of March 31, 2022, December 31, 2021 ( not 8, March 31, 2022 (Unaudited ) December 31, 2021 (in thousands) Current portion of debt: SBA Paycheck Protection Program loans, mature April 2022 140 $ 314 Convertible note payable, matures March 1, 2023 $ 50 — Debt discount, net of amortization (16 ) — Total current portion of debt $ 174 $ 314 Long-term debt: SBA EIDL Loan, matures July 2050 150 150 Convertible note payable, matures March 1, 2023 $ — 50 Debt discount, net of amortization — (20 ) Total long-term portion of debt $ 150 $ 180 Total $ 324 $ 494 For the three March 31, 2022 2021, The following discussion includes debt instruments to which amendments were made or included other activity that management deemed appropriate to disclose. Each of the debt instruments contained in the above table are disclosed more fully in the financial statements contained in the Company’s Form 10 March 30, 2022. SBA Program Loans In April 2020 , two 1%. February 7, 2022, $174,000; March 19, 2021,

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5. Issuance of Common Stock in exchange for payment of payables Payment of Officer Salaries No shares were issued as payment of officer salary in the three March 31, 2022. On March 31, 2021, Payment of Consultant Fees On March 31, 2022, On March 31, 2021, Stock Option Expense During the three March 31, 2022 2021, 2018 2007 8 2018 On June 22, 2018, 2018 “2018 may 2018 2018 January 1 st Activity for our stock options under the 2018 three March 31, 2022 2021, Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding Price per share share Value (1) Balance, December 31, 2021 23,186,142 $0.16 – 0.40 $ 0.19 Granted 2,621,229 0.12 – 0.23 0.23 Expired — — — Balance, March 31, 2022 25,807,371 $0.22 – 0.40 $ 0.19 Non-vested (4,742,688 ) 0.17 – 0.40 0.22 Vested, March 31, 2022 21,064,683 $0.16 – 0.40 $ 0.19 $ 1,015,000 Balance, December 31, 2020 18,865,525 $0.16 – 0.40 $ 0.19 Granted 1,217,670 0.12 – 0.23 0.19 Expired — — — Balance, March 31, 2021 20,083,195 $0.12 – 0.40 $ 0.20 ( 1 Aggregate intrinsic value based on closing common stock price of $0.23 at March 31, 2022. The options granted to purchase 2,621,229 shares during the three March 31, 2022 $96,000; four The options granted to purchase 1,217,670 shares during the three March 31, 2021 four 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may September 7, 2017. September 2017, Activity for our stock options under the 2007 three March 31, 2022 2021 Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding price per share share Value (1) Balance, December 31, 2021 2,879,246 $0.23 – 0.94 $ 0.49 Expired — — — Balance, March 31, 2022 2,879,246 $0.23 – 0.94 $ 0.49 $ — Balance, December 31, 2020 5,689,363 $0.23 – 0.94 $ 0.44 Expired (920,000 ) 0.45 – 0.50 0.49 Balance, March 31, 2021 4,769,363 $0.23 – 0.94 $ 0.43 ( 1 March 31, 2022. Non-Plan Options issued During the three March 31, 2022, During the three March 31, 2021, Activity of our non-plan stock options issued for the three March 31, 2022 2021 Weighted Non-plan average Aggregate Options Exercise price per Intrinsic outstanding price per share share value (1) Balance, December 31, 2021 20,119,207 $0.12 – 0.83 $ 0.38 Granted 32,609 0.23 0.23 Balance, March 31, 2022 20,151,816 $0.12 – 0.83 $ 0.39 Non-vested (1,206,986 ) 0.23 – 0.45 0.44 Vested, March 31, 2022 18,944,830 $0.12 – 0.83 $ 0.38 $ 130,000 Balance, December 31, 2020 20,749,583 $0.17 – 1.00 $ 0.41 Granted 43,956 0.23 0.23 Balance, March 31, 2021 20,793,539 $0.17 – 1.00 $ 0.41 ( 1 March 31, 2022.

Note 6 - Warrants

Note 6 - Warrants	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Warrants [Text Block]	Note 6. We issued warrants to purchase our common stock, at various prices for the three March 31, 2022 2021, Exercise Aggregate Warrants Exercise price per Intrinsic outstanding price per share share value (1) Balance, December 31, 2021 36,765,502 $0.16 – 1.00 $ 0.27 Issued 10,393,936 0.20 – 0.25 0.22 Expired (388,889 ) 0.22 0.22 Balance, March 31, 2022 46,770,549 $0.14 – 1.00 $ 0.26 $ 342,000 Balance, December 31, 2020 32,980,989 $0.16 – 1.00 $ 0.29 Issued 1,975,000 0.14 – 0.18 0.16 Expired (746,528 ) 0.19 – 0.22 0.20 Balance, March 31, 2021 34,209,461 $0.14 – 1.00 $ 0.29 ( 1 – Aggregate intrinsic value based on closing common stock price of $0.23 at March 31, 2022. Warrants issued in 2020 During the three March 31, 2022, 2020 3 six five During the three March 31, 2021, 2020 3 six five Fair Value – Interest Expense To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the relative fair values are amortized over the life of the warrant. For the determination of expense of warrants issued for services, extinguishment of debt and settlement, management also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: March 31, 2022 March 31, 2021 Risk free interest rate — % 0.71% Expected volatility — % 100% Expected dividend yield — — Forfeiture rate — — Expected life in years — .5 - 5 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7. Accounts payable and accrued expenses included the following (in thousands): March 31, 2021 December 31, 2020 Accounts payable and accrued expense $ 461 $ 349 Accrued interest 25 25 Accrued payroll 186 185 Total accounts payable and accrued expenses $ 672 $ 559 Accounts payable and accrued expenses includes ordinary business payables incurred by the Company and its operational subsidiaries. See Note 8,

Note 8 - Noncontrolling Interes

Note 8 - Noncontrolling Interest - Clyra Medical	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8. Clyra Medical We consolidate the operations of our partially owned subsidiary Clyra Medical, of which we owned 58% of its outstanding shares as of March 31, 2022. BioLargo and its partially owned subsidiary Clyra Medical entered into an agreement dated March 3, 2022, Debt Obligations of Clyra Medical Inventory Line of Credit On June 30, 2020, March 31, 2022, one June 30, 2022, may Clyra Medical other asset On December 30, 2015, four June 30, 2020, three not 2021, Clyra Medical Equity transactions As of March 31, 2022, Shareholder Shares Percent BioLargo, Inc. 51,249 58 % Sanatio Capital 18,704 21 % Other 19,118 21 % Total 89,071 Sales of Common Shares There were no sales of Clyra shares during the three March 31, 2022. During the three March 31, 2021, Stock Options Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. As of December 31, 2021, three March 31, 2022 2021, three March 31, 2022 2021 no Clyra Accounts Payable and Accrued Expenses Clyra had the following accounts payable and accrued expenses as follows: March 31, 2022 December 31, 2021 Accounts payable and accrued expense $ 201 $ 149 Accrued interest — 51 Accrued payroll 3 30 Total Clyra Medical accounts payable and accrued expenses $ 204 $ 230

Note 9 - Business Segment Infor

Note 9 - Business Segment Information	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 9. BioLargo currently has four four 1. ONM Environmental -- which sells odor and volatile organic control products and services (located in Westminster, California); 2. Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies; 3. BLEST -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed (located in Oak Ridge, Tennessee); and 4. BioLargo Water (“Water”) -- which historically focused entirely on R&D, and has now shifted its focus to commercializing the AOS technology (located in Edmonton, Alberta Canada). Historically, none third The segment information for the three March 31, 2022 2021, March 31, 2022 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ 2 $ 600 $ 10 $ 545 $ — $ (192 ) $ 965 Intersegment revenue (2 ) (2 ) — (188 ) — 192 — Research and development (265 ) — (16 ) (108 ) (197 ) 194 (392 ) Operating income (loss) (1,220 ) 13 (240 ) (35 ) (228 ) — (1,710 ) Grant income — — — — 5 — 5 Interest expense (6 ) — (7 ) — — — (13 ) Net income (loss) (1,226 ) 187 (247 ) (35 ) (223 ) — (1,544 ) March 31, 2021 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ 7 $ 320 $ 115 $ 388 $ 8 $ (267 ) $ 571 Intersegment revenue (7 ) — — (260 ) — 267 — Research and development (336 ) — (2 ) (105 ) (119 ) 260 (327 ) Operating loss (923 ) (176 ) (439 ) (183 ) (137 ) — (1,858 ) Grant income — — — — 30 — 30 Interest expense (55 ) — (38 ) — — — (93 ) Net loss (978 ) (176 ) (434 ) (183 ) (107 ) — (1,878 ) As of March 31, 2022 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 788 $ 590 $ 817 $ 502 $ 177 $ (46 ) $ 2,828 Right of use 200 — — 221 — — 421 Investment in South Korean joint venture 40 — — — — — 40 Total $ 1,028 $ 590 $ 817 $ 723 $ 177 $ (46 ) $ 3,289 As of December 31, 2021 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 690 $ 451 $ 832 $ 445 $ 152 $ (47 ) $ 2,522 Right of use 222 — — 231 — — 453 Investment in South Korean joint venture 48 — — — — — 48 Total 960 451 832 676 152 (47 ) $ 3,023

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 10. Office Leases We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. For the three March 31, 2022 2021, March 31, 2022, four We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. On January 1, 2019, 842 not not August 2024. four four not one three September 2022, one five five one None no not no

Note 11 - Subsequent Events

Note 11 - Subsequent Events	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 11. Management has evaluated subsequent events through the date of the filing of this report and management noted the following for disclosure. Unit Offering Investments On April 19, 2022, four two six five

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and partially-owned subsidiaries BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of March 31, 2022 December 31, 2021, March 31, 2022 December 31, 2021 BioLargo, Inc. and subsidiaries $ 951 $ 941 Clyra Medical Technologies, Inc. 23 21 Total $ 974 $ 962
Receivable [Policy Text Block]	Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of March 31, 2022 December 31, 2021, $ 13,000
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three March 31, 2022 2020, 10% March 31, 2022 March 31, 2021 Customer A 29 % <10 % Customer B 14 % <10 % Customer C <10 % 39 % Customer D <10 % 16 % Customer E <10 % 13 % Customer F <10 % 12 % We had two customers that each accounted for more than 10% March 31, 2022, two December 31, 2021, March 31, 2022 December 31, 2021 Customer D 29 % <10 % Customer E 24 % <10 % Customer F <10 % 32 % Customer G <10 % 12 %
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of March 31, 2022, December 31, 2021, $3,000. March 31, 2022 December 31, 2021 Raw material $ 129 $ 108 Finished goods 141 133 Total $ 270 $ 241
Other Assets, Policy [Policy Text Block]	Other Assets Other non-current assets consisted of (i) security deposits of $35,000 related to our business offices, and (ii) three $29,000.
Equity Method Investments [Policy Text Block]	Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not three March 31, 2022 March 31, 2021
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not three March 31, 2022 2021, Nevertheless, for the year ended December 31, 2021, 2021 $342,000.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three March 31, 2022 2021,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Share-Based Payment Arrangement [Policy Text Block]	Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three March 31, 2022 2021: 2022 2021 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.32 % 2.32 % 1.73 % 0.93 – 1.73% Expected volatility 117 % 117 % 124 % 124% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not
Warrant Policy [Policy Text Block]	Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible debt instrument is examined for any intrinsic beneficial conversion feature (“BCF”) of which the conversion price is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible debt instrument and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. At present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered, or product is received.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: We have revenue from four BLEST identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. BLEST’s contracts typically call for invoicing for time and materials incurred for that contract. A few contracts have called for milestone or fixed cost payments, where BLEST invoices an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. We recognized $118,000 in the three March 31, 2022, December 31, 2021. March 31, 2022, no In the event that we generate revenues from royalties or license fees from our intellectual property, we anticipate a licensee would pay a license fee in one
Government Grants [Policy Text Block]	Government Grants We have been awarded multiple research grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no March 31, 2022, December 31, 2021. The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not March 31, 2022. The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of March 31, 2022 December 31, 2021,
Tax Credits [Policy Text Block]	Tax Credits Our research and development activities in Canada may not
Lessee, Leases [Policy Text Block]	Leases We adopted ASU 2016 12 842, No March 31, 2022, $ 421,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 1 not not 2 December 15, 2021, December 15, 2023, not In January 2020, No 2020 01, 321 323 815 321, 323, 815”. 321 323 2016 01. 321 10 35 2, 321 not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	March 31, 2022 December 31, 2021 BioLargo, Inc. and subsidiaries $ 951 $ 941 Clyra Medical Technologies, Inc. 23 21 Total $ 974 $ 962
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	March 31, 2022 March 31, 2021 Customer A 29 % <10 % Customer B 14 % <10 % Customer C <10 % 39 % Customer D <10 % 16 % Customer E <10 % 13 % Customer F <10 % 12 % March 31, 2022 December 31, 2021 Customer D 29 % <10 % Customer E 24 % <10 % Customer F <10 % 32 % Customer G <10 % 12 %
Schedule of Inventory, Current [Table Text Block]	March 31, 2022 December 31, 2021 Raw material $ 129 $ 108 Finished goods 141 133 Total $ 270 $ 241
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2022 2021 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.32 % 2.32 % 1.73 % 0.93 – 1.73% Expected volatility 117 % 117 % 124 % 124% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10

Note 4 - Debt Obligations (Tabl

Note 4 - Debt Obligations (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2022 (Unaudited ) December 31, 2021 (in thousands) Current portion of debt: SBA Paycheck Protection Program loans, mature April 2022 140 $ 314 Convertible note payable, matures March 1, 2023 $ 50 — Debt discount, net of amortization (16 ) — Total current portion of debt $ 174 $ 314 Long-term debt: SBA EIDL Loan, matures July 2050 150 150 Convertible note payable, matures March 1, 2023 $ — 50 Debt discount, net of amortization — (20 ) Total long-term portion of debt $ 150 $ 180 Total $ 324 $ 494

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding Price per share share Value (1) Balance, December 31, 2021 23,186,142 $0.16 – 0.40 $ 0.19 Granted 2,621,229 0.12 – 0.23 0.23 Expired — — — Balance, March 31, 2022 25,807,371 $0.22 – 0.40 $ 0.19 Non-vested (4,742,688 ) 0.17 – 0.40 0.22 Vested, March 31, 2022 21,064,683 $0.16 – 0.40 $ 0.19 $ 1,015,000 Balance, December 31, 2020 18,865,525 $0.16 – 0.40 $ 0.19 Granted 1,217,670 0.12 – 0.23 0.19 Expired — — — Balance, March 31, 2021 20,083,195 $0.12 – 0.40 $ 0.20 Weighted Average Aggregate Options Exercise Price per intrinsic Outstanding price per share share Value (1) Balance, December 31, 2021 2,879,246 $0.23 – 0.94 $ 0.49 Expired — — — Balance, March 31, 2022 2,879,246 $0.23 – 0.94 $ 0.49 $ — Balance, December 31, 2020 5,689,363 $0.23 – 0.94 $ 0.44 Expired (920,000 ) 0.45 – 0.50 0.49 Balance, March 31, 2021 4,769,363 $0.23 – 0.94 $ 0.43 Weighted Non-plan average Aggregate Options Exercise price per Intrinsic outstanding price per share share value (1) Balance, December 31, 2021 20,119,207 $0.12 – 0.83 $ 0.38 Granted 32,609 0.23 0.23 Balance, March 31, 2022 20,151,816 $0.12 – 0.83 $ 0.39 Non-vested (1,206,986 ) 0.23 – 0.45 0.44 Vested, March 31, 2022 18,944,830 $0.12 – 0.83 $ 0.38 $ 130,000 Balance, December 31, 2020 20,749,583 $0.17 – 1.00 $ 0.41 Granted 43,956 0.23 0.23 Balance, March 31, 2021 20,793,539 $0.17 – 1.00 $ 0.41

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Aggregate Warrants Exercise price per Intrinsic outstanding price per share share value (1) Balance, December 31, 2021 36,765,502 $0.16 – 1.00 $ 0.27 Issued 10,393,936 0.20 – 0.25 0.22 Expired (388,889 ) 0.22 0.22 Balance, March 31, 2022 46,770,549 $0.14 – 1.00 $ 0.26 $ 342,000 Balance, December 31, 2020 32,980,989 $0.16 – 1.00 $ 0.29 Issued 1,975,000 0.14 – 0.18 0.16 Expired (746,528 ) 0.19 – 0.22 0.20 Balance, March 31, 2021 34,209,461 $0.14 – 1.00 $ 0.29
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	March 31, 2022 March 31, 2021 Risk free interest rate — % 0.71% Expected volatility — % 100% Expected dividend yield — — Forfeiture rate — — Expected life in years — .5 - 5

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2021 December 31, 2020 Accounts payable and accrued expense $ 461 $ 349 Accrued interest 25 25 Accrued payroll 186 185 Total accounts payable and accrued expenses $ 672 $ 559

Note 8 - Noncontrolling Inter_2

Note 8 - Noncontrolling Interest - Clyra Medical (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Shareholder Shares Percent BioLargo, Inc. 51,249 58 % Sanatio Capital 18,704 21 % Other 19,118 21 % Total 89,071
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2021 December 31, 2020 Accounts payable and accrued expense $ 461 $ 349 Accrued interest 25 25 Accrued payroll 186 185 Total accounts payable and accrued expenses $ 672 $ 559
Clyra Medical [Member]
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2022 December 31, 2021 Accounts payable and accrued expense $ 201 $ 149 Accrued interest — 51 Accrued payroll 3 30 Total Clyra Medical accounts payable and accrued expenses $ 204 $ 230

Note 9 - Business Segment Inf_2

Note 9 - Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	March 31, 2022 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ 2 $ 600 $ 10 $ 545 $ — $ (192 ) $ 965 Intersegment revenue (2 ) (2 ) — (188 ) — 192 — Research and development (265 ) — (16 ) (108 ) (197 ) 194 (392 ) Operating income (loss) (1,220 ) 13 (240 ) (35 ) (228 ) — (1,710 ) Grant income — — — — 5 — 5 Interest expense (6 ) — (7 ) — — — (13 ) Net income (loss) (1,226 ) 187 (247 ) (35 ) (223 ) — (1,544 ) March 31, 2021 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ 7 $ 320 $ 115 $ 388 $ 8 $ (267 ) $ 571 Intersegment revenue (7 ) — — (260 ) — 267 — Research and development (336 ) — (2 ) (105 ) (119 ) 260 (327 ) Operating loss (923 ) (176 ) (439 ) (183 ) (137 ) — (1,858 ) Grant income — — — — 30 — 30 Interest expense (55 ) — (38 ) — — — (93 ) Net loss (978 ) (176 ) (434 ) (183 ) (107 ) — (1,878 ) As of March 31, 2022 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 788 $ 590 $ 817 $ 502 $ 177 $ (46 ) $ 2,828 Right of use 200 — — 221 — — 421 Investment in South Korean joint venture 40 — — — — — 40 Total $ 1,028 $ 590 $ 817 $ 723 $ 177 $ (46 ) $ 3,289 As of December 31, 2021 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 690 $ 451 $ 832 $ 445 $ 152 $ (47 ) $ 2,522 Right of use 222 — — 231 — — 453 Investment in South Korean joint venture 48 — — — — — 48 Total 960 451 832 676 152 (47 ) $ 3,023

Note 1 - Business and Organiz_2

Note 1 - Business and Organization (Details Textual)	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total	$ (1,544,000)	$ (1,878,000)
Net Cash Provided by (Used in) Operating Activities, Total	(1,140,000)	(845,000)
Working Capital (Deficit)	804,000
Assets, Current, Total	2,048,000		$ 1,801,000
Revenue from Contract with Customer, Including Assessed Tax	$ 965,000	$ 571,000
Number of Wholly-Owned Subsidiaries	4
BioLargo Engineering, Science & Technologies, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent	89.00%
Clyra Medical Technologies [Member]
Noncontrolling Interest, Ownership Percentage by Parent	58.00%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Mar. 20, 2020USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Accounts Receivable, Allowance for Credit Loss, Current		$ 12,000		$ 13,000
Inventory Valuation Reserves, Ending Balance		3,000		3,000
Security Deposit		35,000
Income (Loss) from Equity Method Investments		(8,000)	$ (10,000)
Impairment, Long-Lived Asset, Held-for-Use, Total		0	$ 0	342,000
Contract With Customer, Liability, Revenue Recognized During Period		118,000
Contract with Customer, Liability, Total				89,000
Unrecognized Tax Benefits, Ending Balance		0		0
Operating Lease, Right-of-Use Asset		$ 421,000		$ 453,000
Canadian Government Grants [Member]
Number of Grants Received		80
Grants Receivable		$ 3,700,000
Canadian Government Grants [Member] | Minimum [Member]
Grant Term (Month)		6 months
Canadian Government Grants [Member] | Maximum [Member]
Grant Term (Month)		18 months
Other Assets [Member]
Contract with Customer, Receivable, after Allowance for Credit Loss, Total		$ 29,000
Odin Co Ltd [Member]
Payments to Acquire Interest in Joint Venture	$ 100,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	40.00%	40.00%	40.00%
Income (Loss) from Equity Method Investments		$ 8,000	$ 10,000
Odin Co Ltd [Member] | Tomorrow Water [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	30.00%
Odin Co Ltd [Member] | BKT and Tomorrow Water [Member]
Payments to Acquire Interest in Joint Venture	$ 150,000
Patents [Member]
Intangible Assets, Net (Excluding Goodwill), Total		$ 34,000
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers		2		2

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents	$ 974	$ 962
Parent Company [Member]
Cash and Cash Equivalents	951	941
Noncontrolling Interest [Member]
Cash and Cash Equivalents	$ 23	$ 21

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	29.00%	10.00%
Customer D [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	16.00%
Customer D [Member] | Accounts Receivable [Member]
Credit concentration	29.00%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	14.00%	10.00%
Customer E [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	13.00%
Customer E [Member] | Accounts Receivable [Member]
Credit concentration	24.00%
Customer C [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	39.00%
Customer F [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	12.00%
Customer F [Member] | Accounts Receivable [Member]
Credit concentration			32.00%
Customer G [Member] | Accounts Receivable [Member]
Credit concentration			12.00%

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Raw material	$ 129	$ 108
Finished goods	141	133
Total	$ 270	$ 241

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Non Plan [Member]
Risk free interest rate	2.32%	1.73%
Expected volatility	117.00%	124.00%
Life in years (Year)	10 years	10 years
2018 Equity Incentive Plan [Member]
Risk free interest rate	2.32%
Expected volatility	117.00%	124.00%
Life in years (Year)	10 years	10 years
2018 Equity Incentive Plan [Member] | Minimum [Member]
Risk free interest rate		0.93%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Risk free interest rate		1.73%

Note 3 - Sale of Stock for Ca_2

Note 3 - Sale of Stock for Cash (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Proceeds from Issuance of Common Stock	$ 1,202,000	$ 2,106,000
Warrants Issued with 2020 Unit Offering [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term (Month)	6 months	6 months
Warrants Issued with 2020 Unit Offering [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Month)	5 years	5 years
The 2020 Unit Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	5,196,968	875,000
Proceeds from Issuance of Common Stock	$ 856,000	$ 105,000
Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,506,821	12,455,619
Proceeds from Issuance of Common Stock	$ 346,000	$ 2,001,000

Note 4 - Debt Obligations (Deta

Note 4 - Debt Obligations (Details Textual) - USD ($)	Feb. 07, 2022	Apr. 30, 2020	Mar. 31, 2022	Mar. 31, 2021
Interest Expense, Debt, Total			$ 4,000	$ 93,000
Paycheck Protection Program CARES Act [Member] | ONM [Member]
Proceeds from Issuance of Debt		$ 218,000
Extinguishment of Debt, Amount	$ 174,000
Long-Term Debt, Total	$ 44,000
Paycheck Protection Program CARES Act [Member] | BLEST [Member]
Proceeds from Issuance of Debt		96,000
Paycheck Protection Program CARES Act [Member] | Clyra Medical [Member]
Proceeds from Issuance of Debt		$ 43,000

Note 4 - Debt Obligations - Sch

Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt discount, net of amortization	$ (16)	$ 0
Total current portion of debt	174	314
Long-term debt	150	180
Debt discount, net of amortization	0	(20)
Total	324	494
Paycheck Protection Program CARES Act [Member]
Notes payable	140	314
Convertible Note, Maturing On March 1, 2023 [Member]
Convertible notes	50	0
Long-term debt	0	50
Economic Injury Disaster Loan [Member]
Long-term debt	$ 150	$ 150

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Jun. 22, 2018	Sep. 07, 2017	Mar. 31, 2022	Mar. 31, 2021
Stock Issued During Period, Value, Issued for Services					$ 17,000	$ 111,000
Share Price (in dollars per share)	$ 0.23				$ 0.23
2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			40,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares)			2,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					2,621,229	1,217,670
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.23	$ 0.19
The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years
Non Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					32,609	43,956
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.23	$ 0.23
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expense					$ 660,000	$ 424,000
Officer [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)		137,364			0
Shares Issued, Price Per Share (in dollars per share)		$ 0.23				$ 0.23
Stock Issued During Period, Value, Issued for Services		$ 31,000
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)	86,752	610,123
Shares Issued, Price Per Share (in dollars per share)	$ 0.23	$ 0.23			$ 0.23	$ 0.23
Stock Issued During Period, Value, Issued for Services	$ 17,000	$ 80,000
Employees, Consultations, Officers, and Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					2,621,229
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					39,848	300,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.23	$ 0.17
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Payment Arrangement, Expense					$ 96,000	$ 65,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					444,092	296,704
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.23	$ 0.23
Employees [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Payment Arrangement, Expense					$ 362,000	$ 89,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					1,690,257	407,713
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.23	$ 0.23
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					4 years	4 years
Employees [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						1,217,670
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Stock Issued During Period, Value, Issued for Services					$ 97,000	$ 37,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					447,032	213,253
Vendors [Member] | Non Plan [Member]
Shares Issued, Price Per Share (in dollars per share)	$ 0.23	$ 0.23			$ 0.23	$ 0.23
Share-Based Payment Arrangement, Expense					$ 7,000	$ 10,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					32,609	43,956

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Options (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
2018 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		23,186,142	18,865,525
Weighted average exercise price per share, balance (in dollars per share)		$ 0.19	$ 0.19
Options granted (in shares)		2,621,229	1,217,670
Weighted average exercise price per share, granted (in dollars per share)		$ 0.23	$ 0.19
Options expired (in shares)		0	0
Weighted average exercise price per share, Expired (in dollars per share)		$ 0	$ 0
Options Non-vested (in shares)		(4,742,688)
Weighted average exercise price per share, Non-vested (in dollars per share)		$ 0.22
Options Vested (in shares)		21,064,683
Vested, March 31, 2022 (in dollars per share)		$ 0.19
Vested, aggregate intrinsic value	[1]	$ 1,015,000
Options outstanding, balance (in shares)		25,807,371	20,083,195
Weighted average exercise price per share, balance (in dollars per share)		$ 0.19	$ 0.20
2018 Equity Incentive Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)		0.16	0.16
Exercise price per share, granted (in dollars per share)		0.12	0.12
Exercise price per share, Non-vested (in dollars per share)		0.17
Exercise price per share, Vested (in dollars per share)		0.16
Exercise price per share, Expired (in dollars per share)
Exercise price per share, balance (in dollars per share)		0.22	0.12
2018 Equity Incentive Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)		0.40	0.40
Exercise price per share, granted (in dollars per share)		0.23	0.23
Exercise price per share, Non-vested (in dollars per share)		0.40
Exercise price per share, Vested (in dollars per share)		0.40
Exercise price per share, Expired (in dollars per share)
Exercise price per share, balance (in dollars per share)		$ 0.40	$ 0.40
The 2007 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		2,879,246	5,689,363
Weighted average exercise price per share, balance (in dollars per share)		$ 0.49	$ 0.44
Options expired (in shares)			(920,000)
Weighted average exercise price per share, Expired (in dollars per share)			$ 0.49
Options outstanding, balance (in shares)		2,879,246	4,769,363
Weighted average exercise price per share, balance (in dollars per share)		$ 0.49	$ 0.43
The 2007 Equity Incentive Plan [Member] | Minimum [Member]
Weighted average exercise price per share, balance (in dollars per share)		0.23	0.23
Weighted average exercise price per share, Expired (in dollars per share)			0.45
Weighted average exercise price per share, balance (in dollars per share)		0.23	0.23
The 2007 Equity Incentive Plan [Member] | Maximum [Member]
Weighted average exercise price per share, balance (in dollars per share)		0.94	0.94
Weighted average exercise price per share, Expired (in dollars per share)			0.50
Weighted average exercise price per share, balance (in dollars per share)		$ 0.94	$ 0.94
Non Plan [Member]
Options outstanding, balance (in shares)		20,119,207	20,749,583
Weighted average exercise price per share, balance (in dollars per share)		$ 0.38	$ 0.41
Options granted (in shares)		32,609	43,956
Exercise price per share, granted (in dollars per share)		$ 0.23	$ 0.23
Weighted average exercise price per share, granted (in dollars per share)		$ 0.23	$ 0.23
Options Non-vested (in shares)		(1,206,986)
Weighted average exercise price per share, Non-vested (in dollars per share)		$ 0.44
Options Vested (in shares)		18,944,830
Vested, March 31, 2022 (in dollars per share)		$ 0.38
Vested, aggregate intrinsic value	[1]	$ 130,000
Options outstanding, balance (in shares)		20,151,816	20,793,539
Weighted average exercise price per share, balance (in dollars per share)		$ 0.39	$ 0.41
Non Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)		0.12	0.17
Exercise price per share, Non-vested (in dollars per share)		0.23
Exercise price per share, Vested (in dollars per share)		0.12
Exercise price per share, balance (in dollars per share)		0.12	0.17
Non Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)		0.83	1
Exercise price per share, Non-vested (in dollars per share)		0.45
Exercise price per share, Vested (in dollars per share)		0.83
Exercise price per share, balance (in dollars per share)		$ 0.83	$ 1
[1]	Aggregate intrinsic value based on closing common stock price of $0.23 at March 31, 2022.

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - $ / shares	Mar. 31, 2022	Mar. 31, 2021
Share Price (in dollars per share)	$ 0.23
Six-month Warrants in Connection With the 2020 Unit Offering [Member]
Warrants and Rights Outstanding, Term (Month)	6 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	5,196,968	875,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.21	$ 0.14
Five-year Warrants in Connection With the 2020 Unit Offering [Member]
Warrants and Rights Outstanding, Term (Month)	5 years	5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	5,196,968	875,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25	$ 0.18

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Balance, outstanding (in shares)		36,765,502	32,980,989
Issued (in shares)		10,393,936	1,975,000
Expired (in shares)		(388,889)	(746,528)
Expired (in dollars per share)		$ 0.22
Balance, aggregate intrinsic value	[1]	$ 342,000
Balance, outstanding (in shares)		46,770,549	34,209,461
Minimum [Member]
Balance, outstanding, price range (in dollars per share)		$ 0.16	$ 0.16
Granted, price range (in dollars per share)		0.20	0.14
Expired (in dollars per share)			0.19
Balance, outstanding, price range (in dollars per share)		0.14	0.14
Maximum [Member]
Balance, outstanding, price range (in dollars per share)		1	1
Granted, price range (in dollars per share)		0.25	0.18
Expired (in dollars per share)			0.22
Balance, outstanding, price range (in dollars per share)		1	1
Weighted Average [Member]
Balance, outstanding, price range (in dollars per share)		0.27	0.29
Granted, price range (in dollars per share)		0.22	0.16
Expired (in dollars per share)		0.22	0.20
Balance, outstanding, price range (in dollars per share)		$ 0.26	$ 0.29
[1]	Aggregate intrinsic value based on closing common stock price of $0.23 at March 31, 2022.

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	Mar. 31, 2021
Measurement Input, Risk Free Interest Rate [Member]
Risk free interest rate	0.0071
Measurement Input, Price Volatility [Member]
Risk free interest rate	1
Measurement Input, Expected Term [Member] | Minimum [Member]
Risk free interest rate	5
Measurement Input, Expected Term [Member] | Maximum [Member]
Risk free interest rate	5

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Corporate, Non-Segment [Member]
Accounts payable and accrued expense	$ 461
Accrued interest	25
Accrued payroll	186
Total accounts payable and accrued expenses	$ 672
Operating Segments [Member] | Odor-No-More [Member]
Accounts payable and accrued expense		$ 349
Accrued interest		25
Accrued payroll		185
Total accounts payable and accrued expenses		$ 559

Note 8 - Noncontrolling Inter_3

Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual) - USD ($)	Mar. 03, 2022	Jun. 30, 2020	Dec. 30, 2015	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2021
Debt Conversion, Original Debt, Amount				$ 633,000,000	$ 0
Repayments of Lines of Credit				10,000	24,000
Stock Issued During Period, Value, Issued for Services				17,000	111,000
Stock Issued During Period, Value, New Issues				1,202,000	2,106,000
Clyra Medical [Member]
Stock Issued During Period, Value, New Issues				$ 0	$ 50,000
Shares Issued, Price Per Share (in dollars per share)				$ 310	$ 310
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				648	777		14,004
Clyra Medical [Member] | Employees and Consultants [Member]
Stock Issued During Period, Value, Issued for Services				$ 141,000	$ 161,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)				$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years
Clyra Medical [Member] | Employees and Consultants [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate				30.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.32%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate				40.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)				10 years
Clyra Medical [Member] | Beach House Consulting, LLC [Member]
Consulting Services, Monthly Payment			$ 23,000
Consulting Services, Period of Services (Year)			4 years
Stock Issued During Period, Shares, Issued for Services (in shares)						3,639
Consulting Services, Three Consecutive Month Average Revenue Threshold for Consulting Fees to Accrue							$ 250,000
Stock Issued During Period, Value, Issued for Services							$ 591,000
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000,000				$ 1,000,000
Proceeds from Lines of Credit, Total		260,000
Repayments of Lines of Credit		$ 83,000
Long-Term Line of Credit, Total				$ 177,000
Line of Credit Facility, Covenant, Additional Draws, Maximum Percentage of Total Principal Outstanding Allowed				50.00%
Line of Credit Facility, Covenant, Additional Draws, Minimum Amount Allowed				$ 200,000
Debt Instrument, Interest Rate, Stated Percentage				15.00%
Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt after the First 180 Days				60.00%
Stock Issued During Period, Shares, Commitment Fee (in shares)				323
Stock Issued During Period, Value, Commitment Fee				$ 70,000
Conversion of Working Capital Advances into Clyra Medical Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 633,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)	2,042
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 310
Clyra Medical Technologies [Member]
Noncontrolling Interest, Ownership Percentage by Parent				58.00%

Note 8 - Noncontrolling Inter_4

Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details) - Clyra Medical Technology Inc [Member]	Mar. 31, 2022shares
Shares, Outstanding (in shares)	89,071
Biolargo [Member]
Shares, Outstanding (in shares)	51,249
Percent	58.00%
Sanatio [Member]
Shares, Outstanding (in shares)	18,704
Percent	21.00%
Other [Member]
Shares, Outstanding (in shares)	19,118
Percent	21.00%

Note 8 - Noncontrolling Inter_5

Note 8 - Noncontrolling Interest - Summary of Accounts Payable and Accrued Expenses (Details) - Clyra Medical [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accounts payable and accrued expense	$ 201	$ 149
Accrued interest	0	51
Accrued payroll	3	30
Total accounts payable and accrued expenses	$ 204	$ 230

Note 9 - Business Segment Inf_3

Note 9 - Business Segment Information (Details Textual)	3 Months Ended
	Mar. 31, 2022
Number of Operating Segments	4

Note 9 - Business Segment Inf_4

Note 9 - Business Segment Information - Segment Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue	$ 965,000	$ 571,000
Intersegment revenue	0	0
Research and development	(392,000)	(327,000)
Operating income (loss)	(1,710,000)	(1,858,000)
Grant income	5,000	30,000
Interest expense	(13,000)	(93,000)
Net loss	(1,544,000)	(1,878,000)
Tangible assets	2,828,000		$ 2,522,000
Operating Lease, Right-of-Use Asset	421,000		453,000
Investment in South Korean joint venture	40,000		48,000
Total	3,289,000		3,023,000
Tangible assets	2,828,000		2,522,000
Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	40,000		48,000
Corporate, Non-Segment [Member]
Revenue	2,000	7,000
Intersegment revenue	(2,000)	(7,000)
Research and development	(265,000)	(336,000)
Operating income (loss)	(1,220,000)	(923,000)
Grant income	0	0
Interest expense	(6,000)	(55,000)
Net loss	(1,226,000)	(978,000)
Tangible assets	788,000		690,000
Operating Lease, Right-of-Use Asset	200,000		222,000
Total	1,028,000		960,000
Tangible assets	788,000		690,000
Corporate, Non-Segment [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	40,000		48,000
Operating Segments [Member] | Odor-No-More [Member]
Revenue	600,000	320,000
Intersegment revenue	(2,000)	0
Research and development	0	0
Operating income (loss)	13,000	(176,000)
Grant income	0	0
Interest expense	0	0
Net loss	187,000	(176,000)
Tangible assets	590,000		451,000
Operating Lease, Right-of-Use Asset	0		0
Total	590,000		451,000
Tangible assets	590,000		451,000
Operating Segments [Member] | Odor-No-More [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0
Operating Segments [Member] | Clyra Segment [Member]
Revenue	10,000	115,000
Intersegment revenue	0	0
Research and development	(16,000)	(2,000)
Operating income (loss)	(240,000)	(439,000)
Grant income	0	0
Interest expense	(7,000)	(38,000)
Net loss	(247,000)	(434,000)
Operating Segments [Member] | Clyra Medical [Member]
Tangible assets	817,000		832,000
Operating Lease, Right-of-Use Asset	0		0
Total	817,000		832,000
Tangible assets	817,000		832,000
Operating Segments [Member] | Clyra Medical [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0
Operating Segments [Member] | BioLargo Engineering, Science & Technologies, LLC [Member]
Revenue	545,000	388,000
Intersegment revenue	(188,000)	(260,000)
Research and development	(108,000)	(105,000)
Operating income (loss)	(35,000)	(183,000)
Grant income	0	0
Interest expense	0	0
Net loss	(35,000)	(183,000)
Operating Segments [Member] | BLEST [Member]
Tangible assets	502,000		445,000
Operating Lease, Right-of-Use Asset	221,000		231,000
Total	723,000		676,000
Tangible assets	502,000		445,000
Operating Segments [Member] | BLEST [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0
Operating Segments [Member] | BioLargo Water [Member]
Revenue	0	8,000
Intersegment revenue	0	0
Research and development	(197,000)	(119,000)
Operating income (loss)	(228,000)	(137,000)
Grant income	5,000	30,000
Interest expense	0	0
Net loss	(223,000)	(107,000)
Tangible assets	177,000		152,000
Operating Lease, Right-of-Use Asset	0		0
Total	177,000		152,000
Tangible assets	177,000		152,000
Operating Segments [Member] | BioLargo Water [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0
Intersegment Eliminations [Member]
Revenue	(192,000)	(267,000)
Intersegment revenue	192,000	267,000
Research and development	194,000	260,000
Operating income (loss)	0	0
Grant income	0	0
Interest expense	0	0
Net loss	0	$ 0
Consolidation, Eliminations [Member]
Tangible assets	(46,000)		(47,000)
Operating Lease, Right-of-Use Asset	0		0
Total	(46,000)		(47,000)
Tangible assets	(46,000)		(47,000)
Consolidation, Eliminations [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	$ 0		$ 0

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Lease, Expense	$ 63,000	$ 56,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	4 years
Lessee, Operating Lease, Liability, to be Paid, Total	$ 670,000
Lessee, Operating Lease, Discount Rate	18.00%
Corporate Office Lease [Member]
Lessee, Operating Lease, Renewal Term (Year)	4 years
Oak Ridge, Tennessee Facility Lease [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years
Lessee, Operating Lease, Option to Extend Term (Year)	3 years

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($)	Apr. 19, 2022	Mar. 31, 2022	Mar. 31, 2021
Proceeds from Issuance of Common Stock		$ 1,202,000	$ 2,106,000
Subsequent Event [Member] | Warrants Expiring Six Month After Investment Date [Member]
Warrants and Rights Outstanding, Term (Month)	6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.234
Subsequent Event [Member] | Warrants Expiring Five Years After Investment Date [Member]
Warrants and Rights Outstanding, Term (Month)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.2925
Unit Offering Investment [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,723,077
Proceeds from Issuance of Common Stock	$ 726,000